Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422789 | 0.80 | GPR84 (0.43) | IDO1NPC1RAB9AF2LOXL2 | |
| SCHEMBL17433378 | 0.77 | OPRK1 (0.53) | IDO1SMN1; SMN2OPRK1 | |
| SCHEMBL17179281 | 0.73 | AHR (0.45) | LOXL2 | |
| SCHEMBL28178529 | 0.72 | F2 (0.58) | IDO1SMN1; SMN2F2CYP19A1 | |
| SCHEMBL22128280 | 0.71 | IDO1 (0.48) | IDO1 | |
| SCHEMBL17433379 | 0.71 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8309165 | 0.71 | AHR (0.42) | RAB9ALOXL2LMNA | |
| SCHEMBL30920844 | 0.71 | LOXL2 (0.58) | LOXL2 | |
| SCHEMBL28748192 | 0.71 | AHR (0.42) | LOXL2ESR1 | |
| SCHEMBL22529408 | 0.71 | LOXL2 (0.58) | LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | IDO1 2856/4885SMN1; SMN2 4628/4885NPC1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.